OneSource Specialty Pharma shares jump after Q2 results
In short
OneSource Specialty Pharma shares rose nearly 14% after its Q2 update. The company said revenue grew 37% year-on-year and adjusted profit after tax was ₹93.7 crore. It also kept its FY28 targets and said more drug-device combination capacity should help future growth.
This matters because investors reacted positively to the results and outlook. The report does not give the full breakdown of the quarter or say how much of the plan is already in place.
What the reporting says
OneSource Specialty Pharma shares rose nearly 14% after the company reported Q2 revenue growth of 37% year-on-year and adjusted profit after tax of ₹93.7 crore, according to a publisher-supplied summary. The company also maintained its FY28 targets and said expanded drug-device combination capacity should support future growth. The immediate consequence is a sharp share-price rebound, while the report does not provide the full quarterly comparison or management detail.
Why it matters
The publisher-supplied summary says OneSource Specialty Pharma shares gained nearly 14% after Q2 results showed 37% year-on-year revenue growth and adjusted profit after tax of ₹93.7 crore. The company kept its FY28 targets and pointed to expanded drug-device combination capacity as a growth support. The report frames the stock move as a response to earnings and guidance, but it does not include a full margin breakdown or management commentary.